Compare ETG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETG | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | ETG | COLL |
|---|---|---|
| Price | $23.40 | $44.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 132.1K | ★ 512.5K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | N/A | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.17 |
| Revenue Next Year | N/A | $3.65 |
| P/E Ratio | ★ N/A | $28.19 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $14.08 | $23.23 |
| 52 Week High | $18.34 | $50.79 |
| Indicator | ETG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 41.31 |
| Support Level | $22.45 | $44.43 |
| Resistance Level | $23.47 | $48.29 |
| Average True Range (ATR) | 0.23 | 2.15 |
| MACD | -0.02 | -0.30 |
| Stochastic Oscillator | 90.21 | 15.93 |
Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.